 | Info
Sheets |
| | | | | | | | | | | | | | | | | | | | | | |
 | Out-
side |
| | | | |
|
| | | | |
Result : Searchterm 'Distribution Information' found in 0 term [ ] and 21 definitions [ ]
| | 1 - 5 (of 21) nextResult Pages : [1 2 3 4 5] | |  | | |
 |
MRI Resources |
|
| | | | | |  |
| Artirem® |   |
| |
|
Artirem®, the arthrography-specific contrast agent for MRI is a dilute form of Dotarem® with a less concentration of Gd (1:200).
Artirem® has to be injected directly into the joints for better visualisation and delimitation, of the ligament and tendon structures in particular.
|
|
Drug Information and Specification |
| NAME OF COMPOUND |
Gadoterate meglumine, Gd-DOTA |
| DEVELOPER |
Guerbet S.A. |
| CENTRAL MOIETY |
Gd2+ |
| CONTRAST EFFECT |
T1, Predominantly positive enhancement |
| RELAXIVITY |
r1=3.4, r2=4.8, B0=1.0T |
| PHARMACOKINETIC |
Intravascular, extracellular, renal excretion |
| CONCENTRATION |
0,0025 mmol/ml |
| PREPARATION |
Finished product |
| INDICATION |
Arthrography |
| DEVELOPMENT STAGE |
For sale |
| DISTRIBUTOR |
See below |
| PRESENTATION |
Pre-filled syringes of 20 mL |
| DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT! |
|
|
| | | | | |
| | |
| Dotarem® | |
| |
|
Dotarem® is a paramagnetic ionic MRI contrast agent. Extracellular contrast agents like Dotarem®, can be bolus injected because of the relatively low rate of side effects. This contrast medium is useable to enhance signal intensity in magnetic resonance imaging for intracranial and spinal lesions with an abnormal blood brain barrier or abnormal vascularity, and in whole body imaging.
|
|
Drug Information and Specification |
| NAME OF COMPOUND |
Gadoterate meglumine, Gd-DOTA |
| DEVELOPER |
Guerbet S.A. |
| CENTRAL MOIETY |
Gd2+ |
| CONTRAST EFFECT |
T1, Predominantly positive enhancement |
| RELAXIVITY |
r1=3.4, r2=4.8, B0=1.0T |
| PHARMACOKINETIC |
Intravascular, extracellular, renal excretion |
| OSMOLALITY |
1350 mosm/kgH2O |
| CONCENTRATION |
0.5 mol/L |
| DOSAGE |
0.1 mmol/kg / 0.2mL/kg |
| PREPARATION |
Finished product |
| INDICATION |
Neuro/whole body |
| DEVELOPMENT STAGE |
For sale |
| DISTRIBUTOR |
See below |
| PRESENTATION |
Vials of 5, 10, 15, 20mL
Pre-filled syringes of 15 and 20 mL |
| DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT! |
|
|
Distribution Information |
| TERRITORY |
TRADE NAME |
DEVELOPMENT
STAGE |
DISTRIBUTOR |
| EU |
Dotarem® |
for sale |
Guerbet S.A. |
| France, Switzerland |
Artirem® |
for sale |
Guerbet S.A. |
| Australia |
Dotarem® |
for sale |
|
|
| | | |
 Further Reading: |
Basics:
|
|
News & More:
| | | | |
| |
|
MRI Resources |
|
| | | | | |
|
| |
| Endorem™ | |
| |
|
A brand name for ferumoxide (same as Feridex®)
Endorem™ is a black to reddish-brown aqueous colloid of superparamagnetic iron oxide associated with dextran for intravenous administration as a MRI contrast medium for the detection of liver lesions that are associated with an alteration in the RES.
Endorem™ is taken up by macrophages, found only in healthy liver cells but not in most tumors. Tissues such as metastases, primary liver cancer, cysts and various benign tumors, adenomas and hyperplasia retain their native signal intensity, so the contrast between normal and abnormal tissue is increased.
See also Ferumoxide.
|
|
Drug Information and Specification |
| NAME OF COMPOUND |
Dextran-coated ferumoxide, Ami-25
|
| DEVELOPER |
AMAG Pharmaceuticals, Inc., Guerbet S.A.
|
| CENTRAL MOIETY |
Fe2+/Fe3+ |
| CONTRAST EFFECT |
T2, predominantly negative enhancement |
| RELAXIVITY |
r1=40.0, r2=160, B0=0.47T |
| PHARMACOKINETIC |
RES-directed |
| OSMOLALITY |
340 mosm/kgH2O |
| CONCENTRATION |
11.2mg Fe/ml |
| DOSAGE |
15 µmol Fe/kg |
| PREPARATION |
Suspend in an isotonic glucose solution |
| INDICATION |
Liver |
| DEVELOPMENT STAGE |
For sale |
| DISTRIBUTOR |
See below |
| PRESENTATION |
Ampoule of 8 mL |
| DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT! |
|
|
| | | |
| Further Reading: |
Basics:
|
|
News & More:
| | | |
| | |
| Feridex® | |
| |
|
A brand name for ferumoxide (same as Endorem™)
Feridex® is a sterile aqueous colloid of superparamagnetic iron oxide associated with dextran for intravenous administration as a MRI contrast medium for the detection of liver lesions that are associated with an alteration in the RES.
Feridex® is taken up by macrophages, found only in healthy liver cells but not in most tumors. Tissues such as metastases, primary liver cancer, cysts and various benign tumors, adenomas and hyperplasia retain their native signal intensity, so the contrast between normal and abnormal tissue is increased.
Feridex® is a black to reddish-brown aqueous colloid.
See also Ferumoxide.
|
|
Drug Information and Specification |
| NAME OF COMPOUND |
Dextran-coated ferumoxide, Ami-25
|
| DEVELOPER |
AMAG Pharmaceuticals, Inc.
|
| CENTRAL MOIETY |
Fe2+/Fe3+ |
| CONTRAST EFFECT |
T2, predominantly negative enhancement |
| RELAXIVITY |
r1=40.0, r2=160, B0=0.47T |
| PHARMACOKINETIC |
RES-directed |
| OSMOLALITY |
340 mosm/kgH2O |
| CONCENTRATION |
11.2mg Fe/ml |
| DOSAGE |
15 µmol Fe/kg |
| PREPARATION |
Suspend in an isotonic glucose solution |
| INDICATION |
Liver |
| DEVELOPMENT STAGE |
For sale |
| DISTRIBUTOR |
See below |
| PRESENTATION |
Ampoule of 8 mL |
| DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT! |
|
|
| | | |
| Further Reading: |
Basics:
|
|
News & More:
| | | |
| |
|
| |
| FerriSeltz® | |
| |
|
A solution of ferric ammonium citrate (Geritol) used to enhance the delineation of the bowel. With T1 weighted magnetic resonance imaging (MRI) the predominantly positive enhancement helps to distinguish organs and tissues that are adjacent to the upper regions of the gastrointestinal tract. Product name found as both Ferriseltz® and FerriSeltz®.
|
|
Drug Information and Specification |
| NAME OF COMPOUND |
Ferric ammonium citrate (FAC) |
| DEVELOPER |
Otsuka America |
| CENTRAL MOIETY |
Fe2+ |
| CONTRAST EFFECT |
T1, Predominantly positive enhancement |
| RELAXIVITY |
Paramagnetic |
| PHARMACOKINETIC |
Gastrointestinal |
| OSMOLALITY |
|
| CONCENTRATION |
|
| DOSAGE |
|
| PREPARATION |
Dissolve |
| INDICATION |
Bowel marking |
| DEVELOPMENT STAGE |
For sale |
| DISTRIBUTOR |
See below |
| PRESENTATION |
Bags with powder |
| DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT! |
|
|
Distribution Information |
| TERRITORY |
TRADE NAME |
DEVELOPMENT
STAGE |
DISTRIBUTOR |
| USA |
FerriSeltz® |
for sale |
Oncomembrane, Inc. |
|
| | | |
| Further Reading: |
Basics:
|
|
News & More:
| | | |
| |
|
|
MRI Resources |
|
| | | | | | | 1 - 5 (of 21) nextResult Pages : [1 2 3 4 5] |
| |
|
| |
 | Look
Ups |
| |
bottom
(.pdf)
Random Page
top